Get the Stockscreener App
2.70
5.06%
0.13
Cerus Corp stock is traded at $2.70, with a volume of 3.29M.
It is up +5.06% in the last 24 hours and up +11.11% over the past month.
Cerus Corp is a biomedical products company focused on the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria, and parasites. The company sells its INTERCEPT platelet and plasma systems in the United States of America, Europe, the Commonwealth of Independent States countries, the Middle East, and selected countries in other regions around the world. The firm continues to operate in only one segment: Blood safety, and generates revenue from the same.
See More
Previous Close:
$2.57
Open:
$2.65
24h Volume:
3.29M
Relative Volume:
1.46
Market Cap:
$541.00M
Revenue:
$216.56M
Net Income/Loss:
$-9.57M
P/E Ratio:
-54.33
EPS:
-0.0497
Net Cash Flow:
$-1.22M
1W Performance:
+4.25%
1M Performance:
+11.11%
6M Performance:
+25.58%
1Y Performance:
+101.49%
1-Day Range:
$2.59
$2.71
1-Week Range:
$2.41
$2.73
52-Week Range:
$1.15
$3.15
Cerus Corp Stock (CERS) Company Profile
Name
Cerus Corp
Sector
Industry
Phone
(925) 288-6000
Address
1220 CONCORD AVENUE, CONCORD, CA
Compare CERS vs ABT, SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
CERS
Cerus Corp
|
2.70 | 541.00M | 216.56M | -9.57M | -1.22M | -0.0497 |
ABT
Abbott Laboratories
|
88.41 | 153.99B | 45.13B | 6.28B | 7.38B | 3.5895 |
SYK
Stryker Corp
|
307.80 | 118.00B | 25.27B | 3.34B | 4.57B | 8.6334 |
MDT
Medtronic Plc
|
79.34 | 101.86B | 36.36B | 4.84B | 5.43B | 3.7212 |
BSX
Boston Scientific Corp
|
45.29 | 67.32B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
87.36 | 50.30B | 6.30B | 1.07B | 1.09B | 1.8406 |
Cerus Corp Stock (CERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-12-24 | Initiated | Craig Hallum | Buy |
| Jan-20-23 | Downgrade | BTIG Research | Buy → Neutral |
| Jan-17-23 | Downgrade | Stephens | Overweight → Equal-Weight |
| Oct-08-20 | Resumed | BTIG Research | Buy |
| Jun-16-20 | Resumed | Cantor Fitzgerald | Overweight |
| Feb-26-20 | Initiated | BTIG Research | Buy |
| Nov-13-19 | Upgrade | BTIG Research | Neutral → Buy |
| Aug-28-19 | Initiated | Stifel | Buy |
| Aug-23-19 | Resumed | Stephens | Overweight |
| Jan-05-18 | Resumed | Cantor Fitzgerald | Overweight |
| Dec-08-17 | Resumed | BTIG Research | Neutral |
| Jul-07-16 | Resumed | Cantor Fitzgerald | Buy |
| Dec-17-15 | Downgrade | Wedbush | Outperform → Neutral |
| May-02-14 | Reiterated | MLV & Co | Buy |
| Apr-24-13 | Reiterated | Cantor Fitzgerald | Buy |
| Mar-15-13 | Reiterated | MLV & Co | Buy |
| Apr-17-12 | Initiated | Cantor Fitzgerald | Buy |
| Feb-29-12 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Nov-10-11 | Reiterated | MLV & Co | Buy |
| Jun-03-11 | Initiated | Wedbush | Outperform |
| Mar-04-11 | Downgrade | Robert W. Baird | Outperform → Neutral |
| Mar-09-10 | Upgrade | Robert W. Baird | Neutral → Outperform |
| Aug-26-09 | Upgrade | Avondale | Mkt Perform → Mkt Outperform |
View All
Cerus Corp Stock (CERS) Latest News
Cerus StockFriday sector check and transfusion focus - AD HOC NEWS
Cerus Corp (CERS) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Cerus Corp (CERS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Cerus Corp (CERS) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Cerus Corp (CERS) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Cerus Corp (CERS) Valuation: PE, PB & Fair Value Analysis - TradingKey
Cerus Corp (CERS) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Cerus Corp (CERS) Institutional Confidence - TradingKey
Cerus Corp (CERS) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Cerus Corp (CERS) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Cerus to Showcase New Evidence, Innovation and Global Experience with the INTERCEPT Blood System at the 39th International ISBT Congress - Yahoo Finance
Cerus Corporation (CERS) Closes New Debt Facility of Up to $110M - Yahoo Finance
5 Best Genomics Stocks to Buy According to Analysts - Insider Monkey
Cerus Corporation (NASDAQ:CERS) Sees Significant Decrease in Short Interest - MarketBeat
Cerus Corp director Eric Bjerkholt sells $53,180 in stock By Investing.com - Investing.com Australia
Director Eric Bjerkholt Sells 20,454 Shares of Cerus Corp (CERS) - GuruFocus
Cerus Corp director Eric Bjerkholt sells $53,180 in stock - Investing.com UK
Cerus Corp (CERS) director sells 20,454 common shares in open-market trade - Stock Titan
[144] CERUS CORP SEC Filing - Stock Titan
CERS Secures $110M Debt Facility for Enhanced Financial Flexibil - GuruFocus
Cerus Refinances Credit Facilities: $65 Million Term Loan and $30 Million Revolver With MidCap - TradingView
Cerus (NASDAQ: CERS) refinances $65M term loan and $30M revolver - Stock Titan
Cerus secures $110 million debt facility with MidCap Financial By Investing.com - Investing.com Canada
Cerus secures $110 million debt facility with MidCap Financial - Investing.com
$110M refinancing expected to save Cerus up to $3.5M a year - Stock Titan
CERS News | CERUS CORP (NASDAQ:CERS) - ChartMill
Should I buy Cerus (CERS) - Zacks Investment Research
Cerus (NASDAQ: CERS) holders back equity plan, board and auditors - Stock Titan
Cerus COO Vivek Jayaraman sells $50,001 in company stock By Investing.com - Investing.com Nigeria
Cerus COO Vivek Jayaraman sells $50,001 in company stock - Investing.com
Cerus (NASDAQ: CERS) director granted 60,000 RSUs under 2024 equity plan - Stock Titan
Cerus (CERS) director receives 60,000 RSUs under 2024 equity plan - Stock Titan
Cerus (CERS) director Jami Nachtsheim awarded 60,000 RSUs, lifting holdings to 268,362 shares - Stock Titan
Cerus (NASDAQ: CERS) COO executes 10b5-1 sale of 16,667 shares at $3 - Stock Titan
Cerus (NASDAQ: CERS) director receives 60,000 RSUs equity award - Stock Titan
Cerus (CERS) director Gregory Dean granted 60,000 RSUs in equity award - Stock Titan
60,000 RSU award lifts Cerus (CERS) director holdings to 192,386 - Stock Titan
Restricted-stock sales reported by issuer (NASDAQ: CERS) - Stock Titan
Cerus Company Profile & Introduction - Moomoo
Significant Cerus shareholder to oppose CEO and pay chair at June 2 vote - Stock Titan
What’s Fueling New Momentum Across Penny Stock Markets? - Kalkine Media
Cerus Corporation Q1 2026 Earnings: Narrowing Loss Beats Estimates Amid Operational ProgressDividend Earnings Report - newsline.com
Q1 2026 Cerus Corp Earnings Call Transcript - GuruFocus
Cerus Corporation (CERS) Gets Upgraded to Buy Post Q1 by BTIG - Insider Monkey
Cerus Corporation (CERS) Q1 2026 Earnings: EPS Surprises to the Upside as Loss NarrowsCrowd Breakout Signals - Newser
Cerus Promotes its COO to Top Job - Medical Product Outsourcing
Cerus Corp stock (US1570851014): turnaround hopes after sharp rally in blood safety specialist - AD HOC NEWS
5 Oversold Growth Stocks to Invest In Now - Insider Monkey
Are NYSE Penny Stocks Showing Mixed Financial Strength? - Kalkine Media
Cerus Corp stock (US1570851014): blood safety specialist in focus after Q1 2026 update - AD HOC NEWS
Cerus Corp stock (US1570851014): blood safety specialist back in focus after latest business update - AD HOC NEWS
Cerus Corp Stock (CERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.93%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):